食管胃交界部癌的管理：一项叙述性多学科综述
Management of Esophago-Gastric Junction Carcinoma: A Narrative Multidisciplinary Review.
作者信息
Tondolo Vincenzo, Casà Calogero, Rizzo Gianluca, Leone Mariavittoria, Quero Giuseppe, Alfieri Virginia, Boldrini Luca, Bulajic Milutin, Corsi Domenico, Micciché Francesco
机构信息
U.O.C. di Chirurgia Digestiva e del Colon-Retto, Fatebenefratelli Isola Tiberina, Gemelli Isola, 00186 Rome, Italy.
U.O.C. di Radioterapia Oncologica, Fatebenefratelli Isola Tiberina, Gemelli Isola, 00186 Rome, Italy.
出版信息
Cancers (Basel). 2023 May 3;15(9):2597. doi: 10.3390/cancers15092597.
Abstract
Esophagogastric junction (EGJ) carcinoma represents a specific site of disease, given the opportunities for multimodal clinical care and management and the possibilities of combined treatments. It encompasses various clinical subgroups of disease that are heterogeneous and deserve different treatments; therefore, the guidelines have progressively evolved over time, considering the evidence provided by clinical trials. The aim of this narrative review was to summarize the main evidence, which orientates the current guidelines, and to collect the main ongoing studies to address existing gray areas.
摘要
鉴于存在多模式临床护理和管理的机会以及联合治疗的可能性，食管胃交界（EGJ）癌是一种特殊的疾病部位。它包括各种不同的临床疾病亚组，需要不同的治疗方法；因此，考虑到临床试验提供的证据，相关指南也在不断发展。本叙述性综述的目的是总结指导当前指南的主要证据，并收集正在进行的主要研究以解决现有模糊领域的问题。
相似文献
1
Management of Esophago-Gastric Junction Carcinoma: A Narrative Multidisciplinary Review.食管胃交界部癌的管理：一项叙述性多学科综述
Cancers (Basel). 2023 May 3;15(9):2597. doi: 10.3390/cancers15092597.
2
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation.可切除食管和食管胃结合部腺癌治疗的预测性生物标志物：从假说产生到临床验证。
Expert Rev Mol Diagn. 2018 Apr;18(4):357-370. doi: 10.1080/14737159.2018.1454312. Epub 2018 Mar 21.
3
"Sandwich Therapy"-Immunotherapy Plus Concurrent Chemoradiotherapy for Advanced Esophagogastric Junction Carcinoma: Report of Two Cases and Literature Review.“三明治疗法”——免疫疗法联合同步放化疗治疗晚期食管胃交界癌：两例报告及文献综述
Front Oncol. 2022 May 25;12:794153. doi: 10.3389/fonc.2022.794153. eCollection 2022.
4
Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG).辅助 SOX 化疗与 D2 根治性切除局部晚期食管胃结合部（EGJ）腺癌后的同期放化疗比较：一项随机 III 期试验（ARTEG）的研究方案。
Trials. 2021 Oct 30;22(1):753. doi: 10.1186/s13063-021-05617-7.
5
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.食管和胃食管交界处癌，2019 年第 2 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883. doi: 10.6004/jnccn.2019.0033.
6
The surgical management of esophago-gastric junctional cancer.食管胃交界部癌的外科治疗
Surg Oncol. 2016 Dec;25(4):394-400. doi: 10.1016/j.suronc.2016.09.004. Epub 2016 Sep 14.
7
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.比较局部进展期胃癌或食管胃结合部腺癌患者术前放化疗与术前化疗的随机 III 期临床试验方案：PREACT。
BMC Cancer. 2019 Jun 20;19(1):606. doi: 10.1186/s12885-019-5728-8.
8
Recurrence after surgery in esophago-gastric junction adenocarcinoma: Current management and future perspectives.食管胃交界腺癌术后复发：当前治疗及未来展望
Surg Oncol. 2016 Dec;25(4):355-363. doi: 10.1016/j.suronc.2016.08.003. Epub 2016 Aug 16.
9
Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective.食管胃交界部癌的多模式治疗策略：西方视角
J Gastric Cancer. 2019 Jun;19(2):148-156. doi: 10.5230/jgc.2019.19.e19. Epub 2019 May 24.
10
Functional luminal imaging probe in the evaluation of esophago-gastric junction outflow obstruction.功能性腔内成像探针在评估食管胃结合部流出道梗阻中的应用。
Curr Opin Gastroenterol. 2022 Jul 1;38(4):388-394. doi: 10.1097/MOG.0000000000000843.
引用本文的文献
1
Machine learning-based prediction of gastroesophageal junction cancer using electronic medical records.基于机器学习利用电子病历预测胃食管交界癌
Clin Exp Med. 2025 Aug 18;25(1):295. doi: 10.1007/s10238-025-01835-4.
2
Development and validation of a preoperative model for predicting positive proximal margins in adenocarcinoma of the esophagogastric junction and assessing safe margin distance.用于预测食管胃交界腺癌近端切缘阳性及评估安全切缘距离的术前模型的开发与验证
Front Oncol. 2024 Dec 10;14:1503728. doi: 10.3389/fonc.2024.1503728. eCollection 2024.
3
Proximal Margin Involvement Following Total Gastrectomy for Seiwert III Adenocarcinoma: A Management Dilemma.Seiwert III型腺癌全胃切除术后近端切缘受累：治疗困境
Cureus. 2024 Jul 19;16(7):e64945. doi: 10.7759/cureus.64945. eCollection 2024 Jul.
本文引用的文献
1
Integrative proteomic characterization of adenocarcinoma of esophagogastric junction.胃食管结合部腺癌的综合蛋白质组学特征分析。
Nat Commun. 2023 Feb 11;14(1):778. doi: 10.1038/s41467-023-36462-8.
2
Short-term outcomes of Ivor Lewis vs. McKeown esophagectomy: A meta-analysis.艾弗·刘易斯术式与麦克尤恩食管切除术的短期疗效：一项荟萃分析。
Front Surg. 2022 Oct 28;9:950108. doi: 10.3389/fsurg.2022.950108. eCollection 2022.
3
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.食管癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. Epub 2022 Jul 29.
4
Proximal Gastrectomy Versus Total Gastrectomy for Siewert II/III Adenocarcinoma of the Gastroesophageal Junction: a Systematic Review and Meta-analysis.近端胃切除术与全胃切除术治疗食管胃交界部Siewert II/III型腺癌的系统评价和Meta分析
J Gastrointest Surg. 2022 Jun;26(6):1321-1335. doi: 10.1007/s11605-022-05304-1. Epub 2022 Mar 30.
5
Analysis of metastases rates during follow-up after endoscopic resection of early "high-risk" esophageal adenocarcinoma.早期“高危”食管腺癌内镜切除后随访期间转移率的分析。
Gastrointest Endosc. 2022 Aug;96(2):237-247.e3. doi: 10.1016/j.gie.2022.03.005. Epub 2022 Mar 12.
6
Surgical and perioperative treatment strategy for resectable esophagogastric junction cancer.可切除食管胃结合部癌的外科和围手术期治疗策略。
Jpn J Clin Oncol. 2022 May 5;52(5):417-424. doi: 10.1093/jjco/hyac019.
7
Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation.食管癌的现代管理：新辅助、辅助和姑息治疗中的放射肿瘤学
Cancers (Basel). 2022 Jan 15;14(2):431. doi: 10.3390/cancers14020431.
8
Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study.个体风险计算器预测黏膜下（T1b）食管腺癌患者的淋巴结转移：一项多中心队列研究。
Endoscopy. 2022 Feb;54(2):109-117. doi: 10.1055/a-1399-4989. Epub 2021 May 4.
9
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.KEYNOTE-975 研究设计：一项在食管癌患者中进行的根治性放化疗加帕博利珠单抗的 III 期研究。
Future Oncol. 2021 Apr;17(10):1143-1153. doi: 10.2217/fon-2020-0969. Epub 2021 Feb 3.
10
Laparoscopic versus open transhiatal approach for adenocarcinoma of the esophagogastric junction: A systematic review and meta-analysis.腹腔镜与开放经食管裂孔入路治疗食管胃结合部腺癌的系统评价和荟萃分析。
Eur J Surg Oncol. 2021 Apr;47(4):778-788. doi: 10.1016/j.ejso.2020.10.022. Epub 2020 Oct 20.
Zotero 插件